Drugs / LOXO-338
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05024045 | Sep 2021 → Jun 2023 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma +1 | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOXO-338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05024045 ↗ |
| Action | Inhibit | “small-molecule inhibitor of Bcl-2” PMID 40000354 ↗ Jan 2025 |
| Modality | Small molecule | “LOXO-338 is a novel, orally bioavailable small-molecule inhibitor of Bcl-2” PMID 40000354 ↗ Jan 2025 |
| Route | Oral | “LOXO-338 was administered orally as 50 to 300 mg once-daily dose until discontinuation due to progressive disease or unacceptable toxicity.” PMID 40000354 ↗ Jan 2025 |
| Target | BCL2 | “small-molecule inhibitor of Bcl-2” PMID 40000354 ↗ Jan 2025 |